Revolution Medicines (RVMD) stock surged 36% to an all-time high after Phase 3 results showed its drug Daraxonrasib significantly improved survival in pancreatic cancer patients compared to chemotherapy. The study met all key endpoints, and the company plans to submit the data to the FDA, marking a potentially transformative advance.